Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Oct 06, 2022 3:30pm
146 Views
Post# 35010318

RE:Share Price Appreciation Expectations?

RE:Share Price Appreciation Expectations?Reaction will be related to quality of the results. I know it is obvious, but it is what it is. I am sure the market will react in accordance with the quality of the results. If it's spectacular, the SP will rise spectacularly. If efficacy is similar to what we saw in phase Ia, SP will not move much. Also, they need to come up with a link between efficacy and sortilin expression to have a clear proof of concept to validate the whole thing. A proof of concept would push this to a real platform for new PDCs in the future.


PWIB123 wrote: What is the likely value of an announcement of efficacy?  It seems like on this board there is always an excuse as to why something isn't good enough.  From a practical standpoint, should they announce efficacy before a Ph. 2, what should we expect in share price reaction?  I like SPCEO1 idea of $12-$15 by year-end, but we have less than 90 days before year-end and it seems to me we might still see a muted response due to a tiny audience, low share price (so still no real institutional trading), and more reasons why it isn't de-risked far enough.  Maybe a Ph. 2 takes it to another level, and maybe we get that before year-end too.  And a protocol amendment to help escalate timelines.  With trading having been muted and pretty much stalled for so long, it is just hard to believe that all of a sudden we'll see a 500% appreciation on an announcement overnight.  And then there's the matter of when they announce.  The sooner the better.  If they announce this month, then I would expect a huge jump and then a gradual continued increase as more investors jump on board.

Thoughts?  I'd like to just go all in with the extra cash I have ike a poker player right now based on what I'm seeing, but this stock has seen nothing but anguish.  I know it's going to change, but it wouldn't suprise me if it took much longer too.


<< Previous
Bullboard Posts
Next >>